KVL-9
KVL‑9 is an intermediate for constructing KRAS-degrading antibody-drug conjugates (DAC), consisting of a KRAS small-molecule binder, a spacer, a VHL-recruiting ligand, and a cleavable antibody linker. By conjugating with tumor antigen-targeting antibodies, KVL‑9 enables antigen-dependent intracellular delivery and induces VHL‑mediated ubiquitin‑proteasome degradation of KRAS protein. KVL‑9 can be used for the synthesis of DACs. KVL‑9 is applicable to cancer research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 3113309-33-1
- Formel: C140H192F2N38O34S2
- Molecular Weight:3053.38
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
KVL-9 achieves antigen-dependent intracellular delivery via conjugation with tumor antigen-targeting antibodies, releases KRAS degrader inside tumor cells, and degrades KRAS protein through the VHL-mediated ubiquitin-proteasome pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 3113309-33-1
-
Molecular Weight 3053.38
-
Formel C140H192F2N38O34S2
-
SMILES
C[C@@]1(C2=NC(C3=NC(N4[C@H](CN(CCC4)CCCCOC5=CN(N=N5)[C@@H](C(C)C)C(N6[C@@H](C[C@H](C6)O)C(N[C@H](C7=C(C=C(C8=C(C)N=CS8)C(F)=C7)OCC9=CC=C(C=C9)NC([C@H](C)NC([C@H](C)NC(CCC%10=C(C(F)=C(N%11C(C=CC%11=O)=O)C=C%10)OCCCC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)C)=NC=C3)=NO2)C%12=C(CCC1)SC(N)=C%12C#N
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. HY-186226-1.pdf
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)